SHINE Receives $263M DOE Conditional Loan for Chrysalis Fusion Isotope Facility

On April 9, 2026, the US Department of Energy's Office of Energy Dominance Financing announced a $263 million conditional loan commitment to SHINE Technologies for the completion of its Chrysalis facility in Janesville, Wisconsin — set to become the world's largest medical isotope production facility. SHINE uses fusion-based neutron technology with a liquid uranium target to produce molybdenum-99 (Mo-99), a critical medical isotope used in over 40,000 diagnostic procedures daily for heart disease and cancer detection. Currently the US imports Mo-99 entirely from Europe, South Africa, and Australia; approximately one-third of supply is lost to radioactive decay during intercontinental transport. The facility is 75–80% complete and will support approximately 200 construction jobs and 150 permanent positions. SHINE founder and CEO Greg Piefer stated: 'Chrysalis proves that fusion doesn't need to wait for future breakthroughs to create value for millions of people today.' The 15-year DOE loan will enable SHINE to reach first isotope production in 1.5–2 years and full capacity in 3–4 years.